Document is current

Article History

Received: 27 August 2024

Accepted: 1 January 2025

First Online: 16 January 2025

Declarations

:

: Hermann L. Müller has received reimbursement of participation fees for scientific meetings and continuing medical education events from the following companies: Ferring, Lilly, Pfizer, Sandoz/Hexal, Novo Nordisk, IPSEN, Rhythm Pharmaceuticals, and Merck Serono. He has received reimbursement of travel expenses from IPSEN, Rhythm Pharmaceuticals, and lecture honoraria from Pfizer. Julia Beckhaus and Carsten Friedrich have nothing to disclose. Nicolas Touchot is employed by and owns shares of Rhythm Pharmaceuticals. Mathias Flume is the founder and owner of GeneAccess GmbH and employed by Kassenärztliche Vereinigung Westfalen-Lippe. GeneAccess GmbH received payments from Rhythm Pharmaceuticals. Julian Witte and Manuel Batram are employed by Vandage and own shares of Vandage GmbH. Kylie Braegelmann and Bastian Surmann are employed by Vandage. Vandage has received payments from Rhythm Pharmaceuticals, Alexion, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Moderna, Merck & Co., Pfizer, PTC Therapeutics, Sanofi Pasteur, Seqirus, Viatris and consulting fees and grants from AOK Rheinland/Hamburg, BARMER, DAK-Gesundheit, German G-BA, and Techniker Krankenkasse. There are no other competing interests to declare.

: No patient data were collected for this study. The study protocol, which exclusively provides for the use of previously pseudonymized data, was drawn up in accordance with the HARPER specifications () and approved by all authors. According to German data protections within § 75 Sozialgesetzbuch (SGB) X, the guidelines and recommendations of the Good Practice of Secondary Data Analysis (), and the complete pseudonymization of the data by the data holder, ethical approval or informed consent were not required for this study.